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Abstract
Background:  Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum
antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative
staphylococci (CoNS or 'MRSE' in case of methicillin-resistant isolates) in pediatric cancer patients
with a long term central venous access device (CVAD, Port- or/Broviac-/Hickman-catheter type).
Methods:  In a single center prospective 48-months cohort study we compared all patients
receiving anticancer chemotherapy from April 2003 to March 2005 (group 1, heparin lock with 200
IU/ml sterile normal saline 0.9%; Canusal® Wockhardt UK Ltd, Wrexham, Wales) and all patients
from April 2005 to March 2007 (group 2; taurolidine 1.35%/Sodium Citrate 4%; TauroLock™,
Tauropharm, Waldbüttelbrunn, Germany).
Results: In group 1 (heparin), 90 patients had 98 CVAD in use during the surveillance period. 14
of 30 (47%) BSI were 'primary Gram positive BSI due to CoNS (n = 4) or MRSE (n = 10)' [incidence
density (ID); 2.30 per 1000 inpatient CVAD-utilization days].
In group 2 (TauroLock™), 89 patients had 95 CVAD in use during the surveillance period. 3 of 25
(12%) BSI were caused by CoNS. (ID, 0.45). The difference in the ID between the two groups was
statistically significant (P = 0.004).
Conclusion: The use of Taurolidin/Citrate (TauroLock™) significantly reduced the number and
incidence density of primary catheter-associated BSI due to CoNS and MRSE in pediatric cancer
patients.
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Background
The use of long-term central-venous access devices
(CVAD, Port- or Broviac-/Hickman catheter type) contrib-
uted to the success of intensive chemotherapy in pediatric
oncology, but it also increased the risk for infection [1-3].
Catheter-related infections result in an increased length of
hospital stay and in higher costs [4,5]. They drain
resources for nursing care, antimicrobials and for surgical
removal of the device in those cases, which do not
respond to antimicrobial treatment. Since most of these
infections are treated with glycopeptides, they contribute
to the overall selective pressure on glycopeptide-resistant
enterococci [6]. Catheter associated infections may occur
in patients irrespective of neutropenia; in a multicenter
study from Italy 68 of 191 (36%) patients with catheter
associated bloodstream infection did not display neutro-
penia at the time of the diagnosis [3]. In principle, the
catheter-related bloodstream infections (BSI) may result
from contamination/colonization of the catheter hub or
of the internal surface of the catheter lumen, i.e. from the
hands of health-care workers or contaminated infusion
fluids. It may further be related to external surface (skin)
colonization originating at the CVAD exit site [7]. In addi-
tion, a CVAD-related infection may be acquired via the
blood stream, e.g., due to bacterial translocation in
patients with chemotherapy induced mucositis [8] or
from a distant focus of infection [9].
The majority of the hub- and the intraluminal infections
without any other apparent source are caused by coagu-
lase-negative staphylococci (CoNS) [2]. The recently final-
ized German surveillance study for nosocomial infections
in pediatric cancer patients [10] identified CoNS as causa-
tive pathogen in 50 of 138 (36%) bloodstream infections;
38% of the CoNS isolates were resistant to methicillin
(MRSE). In the Italian survey of Viscoli et al., 43 of 191
(23%) of all BSI were caused by CoNS [3].
Taurolidine is a chemically modified amino acid (taurin)
with broad spectrum antimicrobial activity in vitro [11-
14]. Toores-Vierra at al. [14] confirmed the in vitro activity
of taurolidine against a broad range of Gram positive and
Gram negative organisms including oxacillin-resistant S.
aureus and CoNS, vancomycin-resistant enterococci, and
Gram  negative pathogens, including P. aeruginosa and
Stenotrophomonas maltophilia; the MIC 90 results of most
isolates were at least 10 times lower than the concentra-
tion of the Taurolidine-preparation used in this study
(13,5 mg/ml).
A small series of studies investigated the use of taurolidine
in the prevention and (adjuvant) treatment of CVAD-
related infections in dialysis [15,16], long-term parenteral
nutrition [17,18] and as adjunctive treatment in CVAD
infections in adult cancer patients [19]. Two potential
advantages attributed to its use are
(1) taurolidine may prevent the formation of biofilm on
the internal surface of the catheter and inside the subcuta-
neous reservoir of infusion ports [20,21].
(2) no resistance against taurolidine has to be expected in
clinically relevant isolates [12-14,22,23].
Furthermore, taurolidine does not display any significant
toxicity even after high dose intravenous infusion [24].
The prospective 48-months cohort study presented here
investigated the impact of a taurolidine/citrate containing
CVAD lock solution on catheter-associated infections in a
pediatric oncology unit at the Children's Hospital Medical
Center, University of Bonn, Germany.
Methods
Setting
The pediatric oncology unit of the University Children's
Hospital in Bonn, Germany, is a 17-bed tertiary care facil-
ity providing inpatient care for 900 admissions during
about 5,000 inpatient days (~50 newly diagnosed pediat-
ric cancer patients) per year. The CVAD clinical-practice
recommendations of the German Society of Pediatric
Oncology and Hematology (GPOH) have been coordi-
nated by one of the authors (AS), are strictly followed dur-
ing in- and outpatient care, and fully match the CDC-
Recommendations [25] with the following exceptions:
octendine 0.1%/phenoxyethanol 2% (Octenisept®,
Schuelke & Mayr, Norderstedt) is used for local antisepsis
[26,27]. In addition, intravenous administration sets are
changed routinely only once a week [28] unless they have
been used for lipid infusion (once a day) or for blood
product administration (6 hours after the transfusion)
[29]. In this pediatric oncology unit, totally implanted
port catheters are preferably used in patients with conven-
tional chemotherapy regimens (median duration of neu-
tropenia <7 days). Double-lumen Broviac/Hickman
catheters are used in patients for whom an intensive and
complicated treatment course or a stem cell transplanta-
tion is anticipated. As a result of this policy, patients have
ports in place in 60–70% and Broviacs in 30–40% of all
inpatient treatment days.
Patients, inclusion and exclusion criteria
All patients with cancer and a long-term intravenous
access device (CVAD) were eligible. Patients with short
term non-tunnelled central venous catheters and patients
with hematological diseases without neutropenia (i.e.
Blackfan-Diamond or sickle cell anemia) were excluded.
CVAD-related bloodstream infections (BSI) and all epi-
sodes of fever were prospectively evaluated by a studyBMC Infectious Diseases 2008, 8:102 http://www.biomedcentral.com/1471-2334/8/102
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nurse and the principal investigator (pediatric oncologist
and infectious disease consultant).
The following two groups in two consecutive 48-month
surveillance periods were compared: all patients receiving
anticancer chemotherapy from April 2003 to March 2005
(group 1, 200 IE heparin lock in 2 ml sterile normal saline
0.9%; Canusal®  Wockhardt UK Ltd, Wrexham, Wales,
U.K.) and all patients from April 2005 to March 2007
(group 2; taurolidine 1.35%/Sodium Citrate 4%; Tau-
roLock™, Tauropharm, Waldbüttelbrunn, Germany). Six
patients first studied in group 1 were excluded from anal-
ysis in group 2 despite the later use of TauroLock™. Both
lines of the double-lumen Broviac catheters were flushed
and relocked in our outpatient clinic or at home by mem-
bers of our outpatient pediatric oncology care team one to
two times a week. Ports were never flushed while not in
use (no puncture of the port just to flush and re-lock the
lumen). TauroLock™ was also used for intermittent locks
in patients, who were disconnected from the infusion sys-
tem during inpatient stay, but this was only rarely the
case. Patients with clinical signs of infection around the
exit site of the CVAD (at the site of needle access in Ports)
were counted as secondary BSI, if the same bacterial spe-
cies with identical in vitro sensitivity results was detected
in blood cultures and in local wound swabs. In case of a
remove or change of the CVAD, the reason for this inter-
vention was documented. Since in some patients the anti-
cancer treatment period crossed the time frame of the two
surveillance periods and as some patients had to receive
more than one subsequent CVAD, patients were allowed
to be included into both surveillance periods and without
restriction on the number of CVADs subsequently used;
every CVAD was counted separately. Neutropenia was
defined as an absolute neutrophil count < 0.5 × 109/l or a
leukocyte count < 1 × 109/l in absence of a differential
WBC. Except cotrimoxazole for the prevention of Pneumo-
cystis jirovecii pneumonia, no antibiotic prophylaxis/selec-
tive decontamination regimen was administered to the
patients with hematologic malignancies or autologous
stem cell transplantation.
Microbiological methods and interpretation of results
Two blood cultures were collected in all patients with
fever (temperature >38,5°C for at least 4 hours or once
>39°C) under aseptic conditions before the first dose of
antibiotics and were routinely tested according to stand-
ard procedures [30]. In the taurolidine group, the (first) 2
ml proportion of the aspirate, which included the lock,
was discarded; otherwise, false negative cultures might
have been the result of the antimicrobial effect of tauroli-
dine added to the Bactec® culture system (Becton Dickin-
son GmbH, Heidelberg, Germany).
According to the recommendations of the German Society
of Pediatric Hematology and Oncology [31,32], no con-
comitant peripheral blood cultures were investigated.
A 'primary CVAD-related Gram positive BSI' was allocated
to any patient who had a CVAD in place, clinical signs of
infection plus at least two positive blood culture bottles
for CoNS or MRSE taken from a CVAD, and no evidence
of another primary focus of infection.
In our pediatric oncology unit, a prospective surveillance
system, based on CDC's National Nosocomial Infections
Surveillance (NNIS) methods, has been continuously
used since 1998. Methods and results of this surveillance
protocol have been published previously [10,33].
Statistical analysis
Since continuously measured data were non-normally
distributed, median and interquartile range (IQR) was cal-
culated, and exact nonparametric analytical methods
(Fisher's test, Fisher-Freeman-Halton test, Wilcoxon-
Mann-Whitney test) were applied. Incidence densities and
their exact 95% confidence intervals were calculated as
Poisson event rates, and compared by testing for homoge-
neity of rates. All analyses were calculated as two-sided
tests, and P-values < 0.05 were considered to be statisti-
cally significant.
Ethic approval and informed consent
The study protocol was approved by the ethics committee
of the medical faculty, University of Bonn and by the Ger-
man Society of Infectious Diseases in Childhood (DGPI).
Informed consent to participate in the surveillance study
was given by all patients or their legal guardians.
Results
In total, 179 patients were studied. The two resulting
study groups of 90 and 89 patients, respectively, were
comparable as to basic characteristics like age, underlying
illness and relapse status (Tab. 1).
Group 1 (2003–2005) Heparin
In group 1 (heparin), 90 patients had 98 CVAD in use dur-
ing the surveillance period. In 8 patients (9%) the CVAD
had to be changed. Of the initially implanted 90 CVAD, 4
(4.4%) had to be removed because of an infection; of
these, 3 because of a primary Gram positive BSI (MRSE) in
Port catheters (3.3%). In addition, 4 patients experienced
mechanical complications (accidental removal, disloca-
tion or occlusion).
Thirty blood culture-positive BSI were documented in 24
(27%) of the 90 patients in group 1 (Tab. 2 and Fig. 1). Of
these, 14 (47%) were allocated to the category 'primary
Gram positive BSI due to CoNS (n = 4) or MRSE (n = 10)'.BMC Infectious Diseases 2008, 8:102 http://www.biomedcentral.com/1471-2334/8/102
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Table 1: Basic patient characteristics and blood stream infections (BSI).
Item Group 1 
(heparin)
Group 2 
(TauroLock™)
P value
No. of patients 90 89 -
Male (proportion in %) 51 (57) 60 (67) 0.16
Female (proportion in %) 39 (43) 29 (33)
Age (years): median 10.4 7.2 0.52
IQRΔ 5.2 to 14.7 3.7 to 16.1
Range 0.2 to 35.2 0.0 to 35.4
CVAD utilization days
Cumulative No. 6,086 6,705 #
Port 3,672 3,989
Broviac 2,414 2,716
Malignancy No. (%) 0.09
ALL 21 (23) 26 (29)
AML 3 (3) 6 (7)
NHL and HD 15 (17) 7 (8)
Solid tumor 30 (33) 22 (25)
ZNS 18 (20) 27 (30)
MAS 2 (2) 0 (0)
MDS 0 (0) 1 (1)
LCH 1 (1) 0 (0)
Malignancy in relapse No. (%) 16 (18) 13 (15) 0.69
No of patients with 0.41
Port (proportion in %) 68 (76) 62 (70)
Broviac (proportion in %) 22 (24) 27 (30)
CVAD removal due to infection: No. (%) 4 (4.4) 3 (3.4)Ω 1.00
Group 1 = heparin (2003–2005) vs. group 2 = TauroLock™ (2005–2007)
MAS Hemophagocytic lymphohistiocytosis, MDS myelodysplastic syndrome,
LCH Langerhans Cell Histiocytosis.
* CoNS = Coagulase-negative staphylococci.
Δ IQR = Interquartile range, 25–75. Percentile
# Utilization days per individual patient were not available; thus, P-values could not be calculated.
Ω None of these due to Gram positive infections caused by CoNS or MRSE
Table 2: Evaluation of blood stream infections.
Item Group 1 
(heparin)
Group 2 
(TauroLock™)
P value
No. of BSI events 30 25
No. (%) of patients with at least 1 BSI 24 (27) 21 (24) 0.74
No. (%) of BSI with CoNS* or MRSE§ 14 (47) 3 (11) 0.004
CoNS: 4 (13) CoNS: 3 (11)
MRSE: 10 (33) MRSE: 0 (0)
Incidence density‡ for All BSI events (CI95) 4.93 (3.33–7.04) 3.82 (2.52–5.56) 0.35
Incidence density‡ calculated with the number of specific isolates
BSI with CoNS/MRSE 2.30 (1.26–3.86) 0.45 (0.09–1.31) 0.004
BSI other Gram positive 0.66 (0.18–1.68) 1.19 (0.52–2.35) 0.32
BSI E. coli 0.66 (0.18–1.68) 1.49 (0.72–2.74) 0.15
BSI all Gram negative 1,97 (1.02–3.44) 2.24 (1.25–3.69) 0.74
Group 1 = heparin (2004–2005) vs. group 2 = TauroLock™ (2005–2006)
* CoNS = coagulase-negative Staphylococci (methicillin-sensitive)
§MRSE = methicillin-resistant coagulase-negative Staphylococci
+ The percentage refers to all documented BSI in this group (100%).
‡ The ID refers to the number of events per 1000 inpatient CVAD utilization days.
Δ IQR = interquartile range, 25–75. PercentileBMC Infectious Diseases 2008, 8:102 http://www.biomedcentral.com/1471-2334/8/102
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The cumulative duration of inpatient CVAD utilization in
group 1 was 6086 days (3672 days for Ports; 2414 days for
Broviacs). Thus, the incidence density (number of events
per 1000 inpatient CVAD utilization days) for primary
Gram positive BSI due to CoNS or MRSE was 2.30. No
patient died related to the infection.
Group 2 (2005–2007) Taurolidine
In group 2 (TauroLock™), 89 patients had 95 CVADs in
place during the 24-months surveillance period. In 6
patients (7%) more than one CVAD had to be implanted
subsequently. No CVAD had to be removed because of a
'primary Gram positive BSI due to CoNS or MRSE'. Three
(3%) had to be removed because of an infection: one port
with local wound infection (S. aureus);, one Broviac with
local wound infection (Pseudomonas aeruginosa), one Bro-
viac after detection of Candida krusei in blood cultures. In
3 patients the CVAD was removed following mechanical
complications.
Twenty-five blood culture-positive bacterial BSI were doc-
umented in group 2 (Tab. 2 and Fig. 1). Of these, 3 (12%)
were due to CoNS, allocated to the category 'primary
Gram positive BSI with CoNS or MRSE'. In one of these
cases the Port-needle had been set under the circum-
stances of an acute life threatening emergency (shock)
Distribution (in %) of blood culture isolates Figure 1
Distribution (in %) of blood culture isolates. [Group 1 heparin; 2003–2005 30 BSI; group 2 TauroLock™; 2005–2007; 25 
BSI).
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without sufficient skin antisepsis. In another patient, a 16
year old female with AML and mucositis, the mother had
re-locked the Broviac at home. On the day of admission
with fever and neutropenia, antibiotic treatment had to be
switched from piperacillin-tazobactam to meropenem,
amikacin, teicoplanin due to clinical sepsis. The attending
physicians did not allocate these symptoms to the multi-
susceptible CoNS detected in the initial blood cultures.
The cumulative duration of CVAD utilization in group 2
was 6705 days (3989 days for Port; 2716 days for Bro-
viac). Thus, the incidence density (per 1000 CVAD utiliza-
tion days) for primary Gram positive BSI due to CoNS or
MRSE was 0.45 (95% CI, 0.09 to 1.31). This was signifi-
cantly lower than the respective incidence density in
group 1 (p = 0.004; Table 2).
No patient died related to the infection.
There was a non-significant trend towards a higher inci-
dence density of E. coli BSI in group 2 versus group 1
(Table 2; 10 vs. 4 infections; incidence density 1.49 vs.
0.66, P = 0.15). This prompted us to take a closer look at
these cases in group 2. The events were not temporally
related (no outbreak).
Five patients with E. coli BSI in group 2 received intensive
(re-) induction treatment for acute leukemia. One 17 year-
old girl with AML in relapse experienced 3 subsequent E.
coli BSI without any clinically documented source. One
patient, a 5 year-old boy with ALL and Down's syndrome
developed a deep local wound infection after bone mar-
row puncture in the diaper area, which probably repre-
sented the source of secondary bacteremia. In one case,
the bacteremia was related to a urinary tract infection
(ALL, female, 16 months).
Safety and convenience issues
No hypersensitivity reactions and no clinical or laboratory
signs of hypocalcaemia were observed. Some patients
complained about the sensation of an uncommon taste
directly after the injection of TauroLock™ when the CVAD
was just flushed without previous aspiration of the lock.
None of the adolescent patients, who were able to com-
municate about this minor adverse effect, refused to con-
tinue the TauroLock™ prophylaxis. In one patient,
TauroLock™ was inadvertently used to lock a peripheral
venous access device. The patient immediately com-
plained about severe local pain. The venous access device
was flushed with normal saline and remained in place
without local signs of phlebitis or extravasation.
Discussion
In our pediatric oncology unit, the routine use of tauroli-
dine 1.35%/sodium-citrate 4% as a lock solution in
patients with long-term CVAD resulted in a statistically
significant and clinically relevant decrease in the inci-
dence density of primary Gram positive CVAD-associated
infections due to CoNS and MRSE. In accordance with
single centre studies performed in patients with hemodi-
alysis catheters [15,16], our results demonstrate the effi-
cacy of the taurolidine lock solution. While the sequential
methodology of our study may not fully delineate the
impact of this intervention; a prospective randomized
double-blind study would be expedient for external vali-
dation.
If one takes the many different possible origins of BSI in
immunocompromised pediatric cancer patients into con-
sideration, it seems difficult to calculate, which propor-
tion of all infections may be preventable through an
intervention, which aims only at the intraluminal coloni-
zation of the device. Gaur et al. (St. Jude Children's
Research Hospital, Memphis), recently investigated infec-
tious complications in pediatric cancer patients in a series
of studies with sophisticated microbiological methods to
confirm the catheter as the primary site of infection. They
came to the conclusion that 36% (21 of 59) of all blood
culture-positive infections were definitely related to the
CVAD-lumen [34,35]. We did not cultivate the first two
ml of the blood sample drawn from the CVAD, which
contained the taurolidine lock at 13.5 mg/ml (2 ml) in
order to avoid false negative results due to the antimicro-
bial effect of taurolidine in the blood culture bottle. Due
to the high in vitro activity of taurolidine at 10 times lower
concentrations it is highly improbable, that cultivation of
these 2 ml would have changed the results.
Our prospective surveillance study of CVAD-associated
infections revealed that the relative risk of a CVAD-associ-
ated infection is up to 21 times higher in inpatients (p <
0.01) [33]. This is the unfavorable consequence of multi-
ple manipulations and prolonged 'hands-on time' during
inpatient care with blood drawings, changes of the admin-
istration sets [28], administration of chemotherapy, anti-
biotics, pain medication, parenteral nutrition [36], and
blood products [37]. Taurolidine can only display its anti-
microbial activity in a CVAD which is actually locked.
Therefore, many opportunities during injection and infu-
sion or blood drawing activities remain in clinical practice
to contaminate the device and subsequently infect the
patient. It remains unknown whether an 'intermittent-
lock approach' with taurolidine (e.g. for 4 hours) would
result in a significant benefit in inpatients.
Although not statistically significant, there have been
more blood stream infections with E. coli observed in the
second surveillance period. A thorough investigation of
each case of E. coli BSI did not reveal any plausible relation
to the use of TauroLock ™. Taurolidine is active against E.BMC Infectious Diseases 2008, 8:102 http://www.biomedcentral.com/1471-2334/8/102
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coli in vitro [13,14]. Most of the patients with E. coli BSI
(as those with BSI due to viridans streptococci) were
intensively treated for acute leukemia, and faced an
increased risk of gastrointestinal translocation due to
mucositis and prolonged neutropenia. In the last 5 years,
E. coli has been the most prevalent Gram negative bacterial
species detected in blood cultures. This may be the case,
because we do not use selective decontamination regi-
mens [38] nor any antibacterial prophylaxis against Gram
negative bacteria. Due to the historical control group
design of our study, we can only speculate, that in group
2 at about 10 prevented Gram positive infections would
have been observed in addition to the Gram negative ones
without the prophylactic use of the taurolidine lock solu-
tion. This issue should be addressed in a prospective ran-
domized study.
In our unit, the mean charges for the management of only
two BSI events (~  5000 per BSI) compensate the higher
12-month acquisition cost (TauroLock™ vs. Canusal™) for
the whole patient population. From an economical per-
spective, the prevention of a single episode would be suf-
ficient, if Broviac CVAD were flushed and relocked always
only once a week [32].
Potential complications (hypersensitivity and hypocal-
caemia) seem to be very unlikely, since the minimal
injected amount of taurolidine is readily metabolized to
taurin and the ≤ 2.5 ml Citrate 4% injection is rapidly
diluted in the vena cava superior, in particular in case of a
slow administration. TauroLock™ must not be used to
lock peripheral venous catheters.
In contrast to a previous study in dialysis patients [15]
which described a lower rate of unassisted catheter pat-
ency (without tissue plasminogen activator instillation)
among patients, who received taurolidine, than among
control patients (32% vs. 76%; P < .001), we could not
detect significant differences between the two groups con-
sidering catheter occlusions (2 in each group) or catheter
related thrombotic events (one in group 1).
Conclusion
This 48 months prospective cohort study from a pediatric
oncology unit showed that the use of Taurolidine 1.35%/
Sodium-Citrate 4% (TauroLock™) as standard lock solu-
tion in long-term CVADs significantly reduced the inci-
dence density of CVAD-associated infections due to CoNS
or MRSE. The described reduction of infectious events
reveals an insistent argument to perform a prospectively
randomized, double-blinded, multicenter study including
a sufficient number of pediatric patients with long term
CVAD.
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